Adiponectin as a biomarker of the metabolic syndrome.

By Miwa Ryo, Tadashi Nakamura, S. Kihara, M. Kumada, S. Shibazaki, M. Takahashi, M. Nagai, Yuji Matsuzawa, T. Funahashi. Circulation Journal, 2004

813 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Adipokines in inflammation and metabolic disease (2011, background): “Adiponectin levels in the plasma and adipose tissue are decreased in obese individuals compared with lean individual”
The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease (2006, background): “Decreased HDL cholesterol level 316 (23) 30 (45) 0.”
New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis (2018, background): “In an in vitro study, insulin reduced the expression of AdipoR1/2 via the PI3K/FOXO1-dependent signaling, and adiponectin increased high-density lipoprotein cholesterol and decreased triglyceride concentrations [120] (Fig.”
Chemerin is a novel adipokine associated with obesity and metabolic syndrome. (2007, background): “Adipose tissue produces and secretes adipokines, and their dysregulation in visceral obesity, may play a role in the development of metabolic syndrome (21).”
Adipocytokines in Obesity and Metabolic Disease (2014, positive): “Adiponectin levels are also negatively associated with adiposity and fasting glucose (Ryo et al. 2004).”
Obesity and inflammation: the linking mechanism and the complications (2016, background): “0 μg/ml) has been associated with increased levels of TG and FBG, decreased HDL-c, hypertension, and increased risk of metabolic syndrome [121].”